Oculis
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- -
- Employees
- 36
- Market Cap
- $553.1M
- Introduction
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.
Oculis Accelerates Enrollment in both DIAMOND Phase 3
Oculis announces accelerated enrollment in Phase 3 DIAMOND trials for OCS-01 eye drops in diabetic macular edema (DME) and expansion of the DIAMOND program committees with globally renowned retina experts. OCS-01, if approved, could transform DME treatment as the first topical eye drop therapy.
Parody PSAs aim to educate youth on safer cannabis use, launched on the anniversary of ...
Get Sensible, by Canadian Students for Sensible Drug Policy, launches a 4-part video series of Cannabis Public Service Announcements to educate young people on harm reduction strategies, addressing the lack of educational resources highlighted in a recent Health Canada report.
Oculis to present phase 3 DIAMOND program updates at Innovate Retina and Eyecelerator 2024
Oculis to present updates on DIAMOND phase 3 trial of OCS-01 eye drops for diabetic macular edema (DME) at Innovate Retina and Eyecelerator. Highlights include stage 1 results at week 12 and stage 2 design for week 52 efficacy and safety assessment. Additionally, topline results from the ACUITY Phase 2 trial of OCS-05 for acute optic neuritis (AON) will be discussed.
Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema
Oculis announces updates on the DIAMOND Phase 3 program with OCS-01 for DME, to be presented at Innovate Retina and Eyecelerator 2024. The program aims to assess the efficacy and safety of OCS-01 eye drops in DME at Week 52, with both DIAMOND-1 and DIAMOND-2 trials enrolling 350 patients each. Additionally, Oculis anticipates topline results from the ACUITY Phase 2 trial with OCS-05 for acute optic neuritis by the end of 2024.
Opthea Limited announces key executive leadership changes and senior hires
Opthea Limited has made executive leadership changes in finance and commercial areas, and hired senior staff in biometrics, clinical operations, and market access. These changes are in preparation for the anticipated clinical trial data in 2025. Key hires include Dan Geffken as interim CFO, Mike Campbell as CCO, Dayong Li as SVP of Biometrics, Jen Watts as VP of Global Clinical Operations, and Anthony Bonifazio as VP of Market Access.
Oculis Closes Phase III Eye Drop Trial Due to Third-Party Administrative Error
Oculis halts Phase III trial of OCS-01 due to third-party error, but FDA accepts data from other trials for NDA submission in Q1 2025. OCS-01 is developed for post-op inflammation, pain, and DME.
© Copyright 2025. All Rights Reserved by MedPath